The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review… This content is
Use the original MHRA report for the full story and treat this page as a linked clinical update rather than a republished article.
ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.